At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
About the role
CI is Connecticut's strategic venture capital arm and one of the most active early-stage investors on the eastern seaboard. CI has a portfolio of 250+ companies across 5 equity funds and a 1 venture debt fund. We have $550 million in assets under management, and our venture portfolio employs 4,000 jobs. In a typical year, we deploy $50 million and write between 60-80 checks. We review 750 companies per year and invite over 100 founders in to pitch us each year.
What they're looking for
- Recent bioscience IPOs : Arvinas, Biohaven Pharmaceuticals, RallyBio, Sema4, Veradermics
- Recent bioscience acquisitions : Avitus, Biorez, Dia Imaging Analysis, Diameter Health, Halda Therapeutics, Medically Home, Modifi Bio, Populi
- Investment origination - building and converting a proprietary pipeline of bioscience opportunities across therapeutics, medtech, diagnostics, tools and digital health
- Deal execution - leading market, product, competitive, technical and valuation analysis, setting and negotiating deal terms, managing the path to close
- Financial modeling and valuation, working with and supporting the rest of the CBIF team
- Investment recommendations and presentations to CI advisory committees and committees of the CI Board of Directors
More about this role
Connecticut Innovations (CI)
CI is Connecticut's strategic venture capital arm and one of the most active early-stage investors on the eastern seaboard. CI has a portfolio of 250+ companies across 5 equity funds and a 1 venture debt fund. We have $550 million in assets under management, and our venture portfolio employs 4,000 jobs. In a typical year, we deploy $50 million and write between 60-80 checks. We review 750 companies per year and invite over 100 founders in to pitch us each year. We add 30 new companies to our portfolio annually, and we also invest as an LP in Connecticut-based venture capital funds.
We measure success through both financial returns and economic impact, including job creation. Over the past decade, CI has generated more than $400 million in returns and cumulatively, our portfolio companies have raised over $8 billion.
- Fiscal 2026 was our best year on record. We generated $76.1 million in cash proceeds from all investment activities. Most of those proceeds came from our strong New Haven bioscience sector. In FY26 actuals, we invested $59.3 million into 75 early-stage companies and venture funds, and those deals pulled an additional $1.2 billion of...
Browse similar: Venture capital jobs